Drugs / CD7 CAR-T cells
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT06787560 | Jan 2025 → Jan 2028 expected | bone marrow failure syndrome | Zhejiang University | Recruiting | No outcome recorded |
| Phase 0 | NCT06769191 | Jan 2025 → Jan 2028 expected | Schimke immuno-osseous dysplasia | Zhejiang University | Recruiting | No outcome recorded |
| Phase 0 | NCT06633328 | Oct 2024 → Oct 2027 expected | aplastic anemia | Zhejiang University | Recruiting | No outcome recorded |
| Phase 0 | NCT05239702 | Feb 2022 → Dec 2024 | Crohn disease, autoimmune disease, dermatomyositis, ulcerative colitis | Zhejiang University | Unknown | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT05212584 | Jul 2022 → Jun 2024 | T lymphoblastic leukemia/lymphoma, refractory hematologic cancer | iCell Gene Therapeutics | Unknown | No outcome recorded |
| Phase 1 | NCT04840875 | Sep 2021 → Sep 2023 | T-cell leukemia, T-cell non-Hodgkin lymphoma | Beijing Boren Hospital | Completed | No outcome recorded |
| Phase 1 | NCT04934774 | Dec 2020 → Jun 2023 | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma | iCell Gene Therapeutics | Unknown | No outcome recorded |
| Phase 1 | NCT04004637 | Aug 2019 → Jun 2021 | T-lymphoblastic lymphoma, acute lymphoblastic leukemia, mature T-cell and NK-cell non-Hodgkin lymphoma | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06925464 | Apr 2025 → Apr 2026 overdue | T-cell non-Hodgkin lymphoma | Beijing GoBroad Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05827835 | Apr 2023 → Apr 2026 overdue | hematologic disorder, neoplasm | Zhejiang University | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04689659 | Dec 2021 → Apr 2024 | T lymphoblastic leukemia/lymphoma | Beijing Boren Hospital | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06871644 | Mar 2025 → Mar 2026 overdue | systemic sclerosis | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Not yet recruiting | No outcome recorded |
| — | NCT05620680 | Oct 2022 → Oct 2026 expected | T lymphoblastic leukemia/lymphoma | Shenzhen University General Hospital | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD7 CAR-T cells | “CD7 CAR T cells will be given once intravenously at one dose (1×106, with an allowance of ± 20%) in patients received previous HSCT donor-derived CAR T cells.” NCT04689659 ↗12“This is a phase 1 clinical trial of autologous CD7-CAR T cells in the treatment of high-risk acute T-cell leukemia / lymphoma.” NCT04840875 ↗ “evaluate the safety of CD7 CAR-T cells for the treatment of subjects with relapsed/refractory AID” NCT06871644 ↗ |
| Known as | Anti-CD7 CAR | “Anti-CD7 CAR is a chimeric antigen receptor immunotherapy treatment designed to treat leukemia/lymphoma expressing CD7 antigen.” NCT04934774 ↗ |
| Action | Deplete | “Although patients' CD7-positive normal T cells were depleted, CD7-negative T cells expanded and likely alleviated treatment-related T-cell immunodeficiency.” PMID 34324392 ↗ Jul 2021 |
| Modality | Cell therapy | “autologous CD7-chimeric antigen receptor (CAR) T cells” PMID 35435984 ↗ Jul 2022 |
| Route | Intravenous | “CD7 CAR T cells will be given once intravenously at one dose (1×106, with an allowance of ± 20%) in patients received previous HSCT donor-derived CAR T cells.” NCT04689659 ↗ |
| Target | CD7 | “PURPOSE: Patients with relapsed or refractory T-cell acute lymphoblastic leukemia (r/r T-ALL) have few options and poor prognosis. The aim was to assess donor-derived anti-CD7...” PMID 34324392 ↗ Jul 2021 |